Zai Lab (ZLAB) Income towards Parent Company (2018 - 2026)
Zai Lab (ZLAB) posted Income towards Parent Company of -$51.0 million for Q1 2026, down 1.2% sequentially from -$50.4 million in Q4 2025, and down 5.32% YoY from -$53.9 million in Q1 2025.
Zai Lab (ZLAB) Income towards Parent Company (2018 - 2026) Analysis & Trends
Zai Lab has reported Income towards Parent Company for 9 years, with the latest figure at -$51.0 million in Q1 2026.
- Quarterly Income towards Parent Company fell 5.32% year-over-year to -$51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$178.1 million (up 29.34% YoY) and the FY2025 annual result came in at -$175.5 million, up 31.73% from the prior year.
- Income towards Parent Company retreated to -$51.0 million in Q1 2026 per ZLAB's latest filing, from -$50.4 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$36.0 million in Q3 2025 and troughed at -$161.2 million in Q3 2022.
- A 5-year average of -$74.2 million and a median of -$61.8 million in 2022 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 70.77% in 2022, down 67.78% in 2022.
- Over 5 years, Income towards Parent Company stood at -$61.8 million in 2022, then plunged by 54.49% to -$95.4 million in 2023, then increased by 14.4% to -$81.7 million in 2024, then surged by 38.29% to -$50.4 million in 2025, then declined by 1.2% to -$51.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$51.0 million, -$50.4 million, and -$36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.83 Mn |
| Mar 31, 2026 | -51.02 Mn |
| Dec 31, 2025 | -50.41 Mn |
| Sep 30, 2025 | -35.96 Mn |
| Jun 30, 2025 | -40.73 Mn |
| Mar 31, 2025 | -48.44 Mn |
| Dec 31, 2024 | -81.68 Mn |
| Sep 30, 2024 | -41.67 Mn |
| Jun 30, 2024 | -80.28 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -95.43 Mn |
| Sep 30, 2023 | -69.15 Mn |
| Jun 30, 2023 | -120.90 Mn |
| Mar 31, 2023 | -49.14 Mn |
| Dec 31, 2022 | -61.77 Mn |
| Sep 30, 2022 | -161.19 Mn |
| Jun 30, 2022 | -137.93 Mn |
| Mar 31, 2022 | -82.17 Mn |
| Dec 31, 2021 | -211.32 Mn |
| Sep 30, 2021 | -96.07 Mn |